Navigation Links
Theramed Corporation to Launch Glenveigh Products, ebb™ and jetty™ at the Society of Obstetricians and Gynecologists of Canada
Date:6/14/2011

MISSISSAUGA, Ontario, June 14, 2011 /PRNewswire/ -- Theramed Corporation ("Theramed") announces that it will launch ebb™ and jetty™ at the 67th Clinical Meeting of the Society of Obstetricians and Gynecologists of Canada. The two newly developed medical devices are to be used to advance the practice of obstetrics, from Glenveigh International, LLC ("Glenveigh"). Both medical device products have been approved for sale by Health Canada, and Theramed will begin distributing these products on June 17th. "We are very excited to partner with Glenveigh Medical in advancing obstetrics for healthy moms and babies in Canada," commented Bill Baugh, Theramed's Chief Executive Officer.

About the ebb™ Complete Tamponade System

ebb™ is a complete tamponade solution for postpartum hemorrhage. Designed by world-renowned maternal-fetal medicine specialists Michael A. Belfort and Gary A. Dildy, the ebb™ balloon is made of a malleable yet extremely strong material, allowing ebb™ to expand and conform to any uterine shape. ebb™ also features a vaginal balloon to control vaginal bleeding and act as an anchor to support the uterine balloon. External ports allow independent control of inflation, deflation, irrigation, and drainage.

About the jetty™ Vaginal Repair Balloon

jetty™ is indicated for use during episiotomy and vaginal laceration repair to temporarily prevent the postpartum discharge of fluids from the vagina in order to assist with the repair procedure. jetty™ provides clarity and cleanliness for a timely, effective repair, and it eliminates the need for vaginal packing with gauze or sponges.

About Theramed Corporation

Theramed Corporation, headquartered in Mississauga, Ontario, is a specialty pharmaceutical company, focused on the development, acquisition, in-licensing, marketing, and distribution of medical products in Canada. The Company is dedicated to bringing new-to-market and well-established healthcare innovations to Canadian Physicians and Hospitals, be these Pharmaceuticals, Biotech products, or Medical Devices. The company currently markets Delatestryl®, Viroptic®, CollatampG® and FSME-IMMUN®.

About Glenveigh International, LLC

Glenveigh is a life science and medical technology company focused on advancing the practice of obstetrics, with aspirations to rapidly become the market leader in the OB/GYN field. Formed in 2004 by a maternal-fetal medicine (MFM) specialist, Glenveigh is founded on the core mission of improving the lives of pregnant mothers and their babies.

For more information on ebb™ or jetty™, marketing medical innovations in Canada, or on Theramed, please contact:

T.W. (Bill) Baugh III
President and CEO
e-mail: bbaugh@theramed.com
Tel: 905-564-5009 or 800-305-4441
http://www.theramed.com





'/>"/>
SOURCE Theramed Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Theramed Secures Exclusive Canadian Distribution Rights for Two Novel Obstetrics Products from Glenveigh
2. Mitsubishi Chemical Medience Corporation Receives 510(k) Clearance for PATHFAST® cTnI-II (cardiac Troponin I) Test in U.S.
3. Spectros Corporation Introduces Continuum®, a Broadband Infrared Sensor for Brain and Gut Oximetry
4. AmbiCom Forms Joint Alliance With E-Care Technology Corporation
5. Volcano Corporation Presentation at William Blair Conference to be Webcast
6. President of Minntech Corporation Injured in Plane Crash
7. Translational Sciences Corporation to Launch OncoTrac™ at the American Society of Clinical Oncology (ASCO) Annual Meeting
8. Luminex Corporation to Present at Jefferies 2011 Global Healthcare Conference
9. Volcano Corporation Presentation at Goldman Sachs Conference to be Webcast
10. EMIT Corporation Receives FDA 510(k) Clearance for HypothermX™ Blood and Fluid Warmer.
11. Statement From Volcano Corporation on Latest St. Jude Lawsuit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... BOSTON , March 27, 2017 ... pharmaceutical company and Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), ... commercialization of innovative therapies based upon tetracycline chemistry, ... sarecycline for the treatment of moderate to severe ... Sarecycline is a once-daily, oral, narrow spectrum tetracycline-derived ...
(Date:3/27/2017)... 2017  PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical ... diseases in children, today reported financial results for ... 31, 2016 and provided an update on its ... make progress during the fourth quarter of 2016 ... primate safety study, and with our lead development ...
(Date:3/24/2017)... , Mar 24, 2017 Research ... Therapy Manufacturing Market, 2017-2027" report to their offering. ... The Cell ... the rapidly growing market of cell therapy manufacturing and focuses ... manufacturing facilities. These therapies are anticipated to emerge as viable ...
Breaking Medicine Technology:
(Date:3/28/2017)... City, NJ (PRWEB) , ... March 28, 2017 ... ... American Camp Association’s Tri-State Camp Conference in Atlantic City March 13-16, was a ... and their team of professional staff discussed strategies for preventing outbreaks among camp ...
(Date:3/28/2017)... ... , ... Silicon Valley Hair Institute, the San Francisco Bay Area leader in ... hair loss. Although hair transplant procedures can be seen as more of a man’s ... be two reasons a woman may see her hair thinning. , “We are used ...
(Date:3/28/2017)... ... 28, 2017 , ... Thank you to all who attended Capio Partners Winter ... event was exclusive to providers and offered an opportunity to collaborate and network with ... Manchester Grand Hyatt where attendees gathered for a lively discussion on trends and issues ...
(Date:3/28/2017)... ... ... Prophets Bones”: a thrilling adventure that reveals the mystery of Kevin’s purpose. “A Prophets Bones” ... and teachers had asked of him that he had neglected to do, but this was ... Creator. There were some who would have felt themselves to be special and better than ...
(Date:3/27/2017)... ... 27, 2017 , ... New patients who have sleep apnea in ... or without a referral. Sleep apnea is often left untreated because patients are not ... and chronic snoring. , Dr. Braasch seeks to raise awareness of sleep apnea ...
Breaking Medicine News(10 mins):